Samsung Bioepis will initiate Phase III trials of a Lucentis biosimilar

September 21, 2017 8:29 AM


Samsung Bioepis is set to begin late-stage clinical trials of its biosimilar version referencing Novartis’ eye drug Lucentis, in South Korea reported The Investor.

According to the newspaper, South Korean health authority, The Ministry of Food and Drug Safety approved the initiation of Phase III clinical trials of the biosimilar candidate SB11 on September 18.

The study will be conducted on 140 patients with wet age-related macular degeneration to compare efficacy and safety between biosimilar candidate SB11 and Lucentis. Lucentis reached global sales of US$3.3 billion in 2016.

Source: The Investor

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!